Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children

Predictors of response to infliximab in paediatric perianal Crohn's disease

“…5 Tolerance of treatment was similar to previous studies in children: the proportion of patients who had adverse events leading to discontinuation in our study was similar to the REACH study, 8% vs. 10% respectively. 20 Contrarily to earlier studies in adults who failed to identify predictive factors of response to IFX in perianal Crohn's disease, [10][11][12] our study shows that a number of fistulas of less than 2, a CD duration of more than , drainage was combined with insertion of a seton. ¶ 'Scheduled' defined as all intervals between infusions during the maintenance treatment <12 weeks.…”

Understanding Infliximab in Crohn’s Disease: The Long-Term Outcomes

“…The medical records of 492 unselected patients (or 464 with outcome data, used here as the denominator to calculate rates) treated with infliximab at the Mayo Clinic (1998-2002) were systematically reviewed. The study showed an 86 % initial response rate (or 80 % calculated on an ITT basis), similar to the 82-89 % reported in most other publications such as the pediatric REACH trial [5], the Edmonton cohort [6], the large Leuven cohort [7], the Leeds cohort [8], and the Targan initial RCT [1] but higher than the short-term response rate achieved in the ACCENT trial (65 %) [2]. This figure (82-89 %) also includes those with partial response, variably defined in the different studies.…”

Decoy oligodeoxynucleotide targeting activator protein-1 (AP-1) attenuates intestinal inflammation in murine experimental colitis

“…Infliximab, a chimeric monoclonal antibody that binds with high affinity and specificity to TNF-a, has been demonstrated to be effective in both induction and maintenance therapy for patients with moderately to severely active CD, and is presently the only biological compound approved for CD therapy. 15,16,48,49 Newer therapeutic monoclonal antibodies targeting interferon (IFN)-g, 50,51 IL-6 receptor, 18 IL-12 p40, 52 and a4-integrin 53 have also been developed, and clinical trials to evaluate the safety and efficiency of those agents for the treatment of IBD are being conducted. Although the development of therapeutic monoclonal antibodies is one of the most important advances in the care of IBD patients during the past decade, current therapies based on such biological agents are not entirely as effective as expected, as several untoward effects including immunogenicity, infusion reactions, and other serious adverse events have been reported.…”